#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Reduced Resting-State Connectivity in the Precuneus is correlated with Apathy in Patients with Schizophrenia A diagnosis of schizophrenia is associated with a heterogeneous psychopathology including positive and negative symptoms.
1-1	0-7	Reduced	_
1-2	8-21	Resting-State	_
1-3	22-34	Connectivity	_
1-4	35-37	in	_
1-5	38-41	the	_
1-6	42-51	Precuneus	_
1-7	52-54	is	_
1-8	55-65	correlated	_
1-9	66-70	with	_
1-10	71-77	Apathy	_
1-11	78-80	in	_
1-12	81-89	Patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-13	90-94	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-14	95-108	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-15	109-110	A	_
1-16	111-120	diagnosis	_
1-17	121-123	of	_
1-18	124-137	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-19	138-140	is	_
1-20	141-151	associated	_
1-21	152-156	with	_
1-22	157-158	a	_
1-23	159-172	heterogeneous	_
1-24	173-188	psychopathology	_
1-25	189-198	including	_
1-26	199-207	positive	_
1-27	208-211	and	_
1-28	212-220	negative	_
1-29	221-229	symptoms	_
1-30	230-231	.	_

Text=The disconnection hypothesis, an early pathophysiological framework conceptualizes the diversity of symptoms as a result of disconnections in neural networks.
2-1	232-235	The	_
2-2	236-249	disconnection	_
2-3	250-260	hypothesis	_
2-4	261-262	,	_
2-5	263-265	an	_
2-6	266-271	early	_
2-7	272-290	pathophysiological	_
2-8	291-300	framework	_
2-9	301-315	conceptualizes	_
2-10	316-319	the	_
2-11	320-329	diversity	_
2-12	330-332	of	_
2-13	333-341	symptoms	_
2-14	342-344	as	_
2-15	345-346	a	_
2-16	347-353	result	_
2-17	354-356	of	_
2-18	357-371	disconnections	_
2-19	372-374	in	_
2-20	375-381	neural	_
2-21	382-390	networks	_
2-22	391-392	.	_

Text=In line with this hypothesis, previous neuroimaging studies of patients with schizophrenia reported alterations within the default mode network (DMN), the most prominent network at rest.
3-1	393-395	In	_
3-2	396-400	line	_
3-3	401-405	with	_
3-4	406-410	this	_
3-5	411-421	hypothesis	_
3-6	422-423	,	_
3-7	424-432	previous	_
3-8	433-445	neuroimaging	_
3-9	446-453	studies	_
3-10	454-456	of	_
3-11	457-465	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-12	466-470	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-13	471-484	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-14	485-493	reported	_
3-15	494-505	alterations	_
3-16	506-512	within	_
3-17	513-516	the	_
3-18	517-524	default	_
3-19	525-529	mode	_
3-20	530-537	network	_
3-21	538-539	(	_
3-22	540-543	DMN	_
3-23	544-545	)	_
3-24	546-547	,	_
3-25	548-551	the	_
3-26	552-556	most	_
3-27	557-566	prominent	_
3-28	567-574	network	_
3-29	575-577	at	_
3-30	578-582	rest	_
3-31	583-584	.	_

Text=The aim of the present study was to investigate the functional connectivity during rest in patients with schizophrenia and with healthy individuals and explore whether observed functional alterations are related to the psychopathology of patients.
4-1	585-588	The	_
4-2	589-592	aim	_
4-3	593-595	of	_
4-4	596-599	the	_
4-5	600-607	present	_
4-6	608-613	study	_
4-7	614-617	was	_
4-8	618-620	to	_
4-9	621-632	investigate	_
4-10	633-636	the	_
4-11	637-647	functional	_
4-12	648-660	connectivity	_
4-13	661-667	during	_
4-14	668-672	rest	_
4-15	673-675	in	_
4-16	676-684	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-17	685-689	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-18	690-703	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-19	704-707	and	_
4-20	708-712	with	_
4-21	713-720	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-22	721-732	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-23	733-736	and	_
4-24	737-744	explore	_
4-25	745-752	whether	_
4-26	753-761	observed	_
4-27	762-772	functional	_
4-28	773-784	alterations	_
4-29	785-788	are	_
4-30	789-796	related	_
4-31	797-799	to	_
4-32	800-803	the	_
4-33	804-819	psychopathology	_
4-34	820-822	of	_
4-35	823-831	patients	_
4-36	832-833	.	_

Text=Therefore, functional magnetic resonance images at rest were recorded of 35 patients with schizophrenia and 41 healthy individuals.
5-1	834-843	Therefore	_
5-2	844-845	,	_
5-3	846-856	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-4	857-865	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-5	866-875	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-6	876-882	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-7	883-885	at	_
5-8	886-890	rest	_
5-9	891-895	were	_
5-10	896-904	recorded	_
5-11	905-907	of	_
5-12	908-910	35	_
5-13	911-919	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-14	920-924	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-15	925-938	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-16	939-942	and	_
5-17	943-945	41	_
5-18	946-953	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-19	954-965	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-20	966-967	.	_

Text=Independent component analysis (ICA) was used to extract resting state networks.
6-1	968-979	Independent	_
6-2	980-989	component	_
6-3	990-998	analysis	_
6-4	999-1000	(	_
6-5	1001-1004	ICA	_
6-6	1005-1006	)	_
6-7	1007-1010	was	_
6-8	1011-1015	used	_
6-9	1016-1018	to	_
6-10	1019-1026	extract	_
6-11	1027-1034	resting	_
6-12	1035-1040	state	_
6-13	1041-1049	networks	_
6-14	1050-1051	.	_

Text=Comparing ICA results between groups indicated alterations only within the network of the DMN.
7-1	1052-1061	Comparing	_
7-2	1062-1065	ICA	_
7-3	1066-1073	results	_
7-4	1074-1081	between	_
7-5	1082-1088	groups	_
7-6	1089-1098	indicated	_
7-7	1099-1110	alterations	_
7-8	1111-1115	only	_
7-9	1116-1122	within	_
7-10	1123-1126	the	_
7-11	1127-1134	network	_
7-12	1135-1137	of	_
7-13	1138-1141	the	_
7-14	1142-1145	DMN	_
7-15	1146-1147	.	_

Text=More explicitly, reduced connectivity in the precuneus was observed in patients with schizophrenia compared to healthy controls.
8-1	1148-1152	More	_
8-2	1153-1163	explicitly	_
8-3	1164-1165	,	_
8-4	1166-1173	reduced	_
8-5	1174-1186	connectivity	_
8-6	1187-1189	in	_
8-7	1190-1193	the	_
8-8	1194-1203	precuneus	_
8-9	1204-1207	was	_
8-10	1208-1216	observed	_
8-11	1217-1219	in	_
8-12	1220-1228	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-13	1229-1233	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-14	1234-1247	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-15	1248-1256	compared	_
8-16	1257-1259	to	_
8-17	1260-1267	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-18	1268-1276	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-19	1277-1278	.	_

Text=Connectivity in this area was negatively correlated with the severity of negative symptoms, more specifically with the domain of apathy.
9-1	1279-1291	Connectivity	_
9-2	1292-1294	in	_
9-3	1295-1299	this	_
9-4	1300-1304	area	_
9-5	1305-1308	was	_
9-6	1309-1319	negatively	_
9-7	1320-1330	correlated	_
9-8	1331-1335	with	_
9-9	1336-1339	the	_
9-10	1340-1348	severity	_
9-11	1349-1351	of	_
9-12	1352-1360	negative	_
9-13	1361-1369	symptoms	_
9-14	1370-1371	,	_
9-15	1372-1376	more	_
9-16	1377-1389	specifically	_
9-17	1390-1394	with	_
9-18	1395-1398	the	_
9-19	1399-1405	domain	_
9-20	1406-1408	of	_
9-21	1409-1415	apathy	_
9-22	1416-1417	.	_

Text=Taken together, the current results provide further evidence for a role DMN alterations might play in schizophrenia and especially in negative symptoms such as apathy.
10-1	1418-1423	Taken	_
10-2	1424-1432	together	_
10-3	1433-1434	,	_
10-4	1435-1438	the	_
10-5	1439-1446	current	_
10-6	1447-1454	results	_
10-7	1455-1462	provide	_
10-8	1463-1470	further	_
10-9	1471-1479	evidence	_
10-10	1480-1483	for	_
10-11	1484-1485	a	_
10-12	1486-1490	role	_
10-13	1491-1494	DMN	_
10-14	1495-1506	alterations	_
10-15	1507-1512	might	_
10-16	1513-1517	play	_
10-17	1518-1520	in	_
10-18	1521-1534	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-19	1535-1538	and	_
10-20	1539-1549	especially	_
10-21	1550-1552	in	_
10-22	1553-1561	negative	_
10-23	1562-1570	symptoms	_
10-24	1571-1575	such	_
10-25	1576-1578	as	_
10-26	1579-1585	apathy	_
10-27	1586-1587	.	_

Text=Methods Participants In total, 76 participants were included in the reported analysis, of which 41 were healthy individuals and of which 35 individuals met the criteria for a diagnosis of schizophrenia following the International Classification for Diseases and Related Health Problems (ICD-10).
11-1	1588-1595	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
11-2	1596-1608	Participants	_
11-3	1609-1611	In	_
11-4	1612-1617	total	_
11-5	1618-1619	,	_
11-6	1620-1622	76	_
11-7	1623-1635	participants	_
11-8	1636-1640	were	_
11-9	1641-1649	included	_
11-10	1650-1652	in	_
11-11	1653-1656	the	_
11-12	1657-1665	reported	_
11-13	1666-1674	analysis	_
11-14	1675-1676	,	_
11-15	1677-1679	of	_
11-16	1680-1685	which	_
11-17	1686-1688	41	_
11-18	1689-1693	were	_
11-19	1694-1701	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-20	1702-1713	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-21	1714-1717	and	_
11-22	1718-1720	of	_
11-23	1721-1726	which	_
11-24	1727-1729	35	_
11-25	1730-1741	individuals	_
11-26	1742-1745	met	_
11-27	1746-1749	the	_
11-28	1750-1758	criteria	_
11-29	1759-1762	for	_
11-30	1763-1764	a	_
11-31	1765-1774	diagnosis	_
11-32	1775-1777	of	_
11-33	1778-1791	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-34	1792-1801	following	_
11-35	1802-1805	the	_
11-36	1806-1819	International	_
11-37	1820-1834	Classification	_
11-38	1835-1838	for	_
11-39	1839-1847	Diseases	_
11-40	1848-1851	and	_
11-41	1852-1859	Related	_
11-42	1860-1866	Health	_
11-43	1867-1875	Problems	_
11-44	1876-1877	(	_
11-45	1878-1884	ICD-10	_
11-46	1885-1886	)	_
11-47	1887-1888	.	_

Text=Patients diagnosed with schizophrenia were recruited at St. Hedwig Hospital, Department for Psychiatry and Psychotherapy of the Charité-Universitätsmedizin Berlin (Germany).
12-1	1889-1897	Patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-2	1898-1907	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-3	1908-1912	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-4	1913-1926	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-5	1927-1931	were	_
12-6	1932-1941	recruited	_
12-7	1942-1944	at	_
12-8	1945-1948	St.	_
12-9	1949-1955	Hedwig	_
12-10	1956-1964	Hospital	_
12-11	1965-1966	,	_
12-12	1967-1977	Department	_
12-13	1978-1981	for	_
12-14	1982-1992	Psychiatry	_
12-15	1993-1996	and	_
12-16	1997-2010	Psychotherapy	_
12-17	2011-2013	of	_
12-18	2014-2017	the	_
12-19	2018-2045	Charité-Universitätsmedizin	_
12-20	2046-2052	Berlin	_
12-21	2053-2054	(	_
12-22	2055-2062	Germany	_
12-23	2063-2064	)	_
12-24	2065-2066	.	_

Text=Healthy individuals were recruited using online advertisements and flyers and did not meet the criteria for any psychiatric disorder based on information acquired with the Mini International Neuropsychiatric Interview (MINI) and were not in current or past psychotherapy of an ongoing mental health-related problem.
13-1	2067-2074	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-2	2075-2086	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-3	2087-2091	were	_
13-4	2092-2101	recruited	_
13-5	2102-2107	using	_
13-6	2108-2114	online	_
13-7	2115-2129	advertisements	_
13-8	2130-2133	and	_
13-9	2134-2140	flyers	_
13-10	2141-2144	and	_
13-11	2145-2148	did	_
13-12	2149-2152	not	_
13-13	2153-2157	meet	_
13-14	2158-2161	the	_
13-15	2162-2170	criteria	_
13-16	2171-2174	for	_
13-17	2175-2178	any	_
13-18	2179-2190	psychiatric	_
13-19	2191-2199	disorder	_
13-20	2200-2205	based	_
13-21	2206-2208	on	_
13-22	2209-2220	information	_
13-23	2221-2229	acquired	_
13-24	2230-2234	with	_
13-25	2235-2238	the	_
13-26	2239-2243	Mini	_
13-27	2244-2257	International	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
13-28	2258-2274	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
13-29	2275-2284	Interview	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
13-30	2285-2286	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
13-31	2287-2291	MINI	_
13-32	2292-2293	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
13-33	2294-2297	and	_
13-34	2298-2302	were	_
13-35	2303-2306	not	_
13-36	2307-2309	in	_
13-37	2310-2317	current	_
13-38	2318-2320	or	_
13-39	2321-2325	past	_
13-40	2326-2339	psychotherapy	_
13-41	2340-2342	of	_
13-42	2343-2345	an	_
13-43	2346-2353	ongoing	_
13-44	2354-2360	mental	_
13-45	2361-2375	health-related	_
13-46	2376-2383	problem	_
13-47	2384-2385	.	_

Text=MRI exclusion criteria such as claustrophobia, neurological disorders and metallic implants applied to all participants.
14-1	2386-2389	MRI	_
14-2	2390-2399	exclusion	_
14-3	2400-2408	criteria	_
14-4	2409-2413	such	_
14-5	2414-2416	as	_
14-6	2417-2431	claustrophobia	_
14-7	2432-2433	,	_
14-8	2434-2446	neurological	_
14-9	2447-2456	disorders	_
14-10	2457-2460	and	_
14-11	2461-2469	metallic	_
14-12	2470-2478	implants	_
14-13	2479-2486	applied	_
14-14	2487-2489	to	_
14-15	2490-2493	all	_
14-16	2494-2506	participants	_
14-17	2507-2508	.	_

Text=Healthy individuals matched the group of patients in terms of age, sex, handedness and level of education (Table 1).
15-1	2509-2516	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-2	2517-2528	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-3	2529-2536	matched	_
15-4	2537-2540	the	_
15-5	2541-2546	group	_
15-6	2547-2549	of	_
15-7	2550-2558	patients	_
15-8	2559-2561	in	_
15-9	2562-2567	terms	_
15-10	2568-2570	of	_
15-11	2571-2574	age	_
15-12	2575-2576	,	_
15-13	2577-2580	sex	_
15-14	2581-2582	,	_
15-15	2583-2593	handedness	_
15-16	2594-2597	and	_
15-17	2598-2603	level	_
15-18	2604-2606	of	_
15-19	2607-2616	education	_
15-20	2617-2618	(	_
15-21	2619-2624	Table	_
15-22	2625-2626	1	_
15-23	2627-2628	)	_
15-24	2629-2630	.	_

Text=Handedness was acquired with Edinburgh Handedness Inventory (n = 75), cognitive functioning was tested using the Brief Assessment of Cognition in Schizophrenia (n = 65) and verbal intelligence with a German Vocabulary Test (n = 72).
16-1	2631-2641	Handedness	_
16-2	2642-2645	was	_
16-3	2646-2654	acquired	_
16-4	2655-2659	with	_
16-5	2660-2669	Edinburgh	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire
16-6	2670-2680	Handedness	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire
16-7	2681-2690	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire
16-8	2691-2692	(	_
16-9	2693-2694	n	_
16-10	2695-2696	=	_
16-11	2697-2699	75	_
16-12	2700-2701	)	_
16-13	2702-2703	,	_
16-14	2704-2713	cognitive	_
16-15	2714-2725	functioning	_
16-16	2726-2729	was	_
16-17	2730-2736	tested	_
16-18	2737-2742	using	_
16-19	2743-2746	the	_
16-20	2747-2752	Brief	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
16-21	2753-2763	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
16-22	2764-2766	of	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
16-23	2767-2776	Cognition	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
16-24	2777-2779	in	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
16-25	2780-2793	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
16-26	2794-2795	(	_
16-27	2796-2797	n	_
16-28	2798-2799	=	_
16-29	2800-2802	65	_
16-30	2803-2804	)	_
16-31	2805-2808	and	_
16-32	2809-2815	verbal	_
16-33	2816-2828	intelligence	_
16-34	2829-2833	with	_
16-35	2834-2835	a	_
16-36	2836-2842	German	_
16-37	2843-2853	Vocabulary	_
16-38	2854-2858	Test	http://maven.renci.org/NeuroBridge/neurobridge#GlucoseToleranceTest
16-39	2859-2860	(	_
16-40	2861-2862	n	_
16-41	2863-2864	=	_
16-42	2865-2867	72	_
16-43	2868-2869	)	_
16-44	2870-2871	.	_

Text=Supplemental information provides details regarding the medication of patients.
17-1	2872-2884	Supplemental	_
17-2	2885-2896	information	_
17-3	2897-2905	provides	_
17-4	2906-2913	details	_
17-5	2914-2923	regarding	_
17-6	2924-2927	the	_
17-7	2928-2938	medication	_
17-8	2939-2941	of	_
17-9	2942-2950	patients	_
17-10	2951-2952	.	_

Text=All procedures of the study were approved by the ethics committee of the Charité-Universitätsmedizin Berlin.
18-1	2953-2956	All	_
18-2	2957-2967	procedures	_
18-3	2968-2970	of	_
18-4	2971-2974	the	_
18-5	2975-2980	study	_
18-6	2981-2985	were	_
18-7	2986-2994	approved	_
18-8	2995-2997	by	_
18-9	2998-3001	the	_
18-10	3002-3008	ethics	_
18-11	3009-3018	committee	_
18-12	3019-3021	of	_
18-13	3022-3025	the	_
18-14	3026-3053	Charité-Universitätsmedizin	_
18-15	3054-3060	Berlin	_
18-16	3061-3062	.	_

Text=All subjects gave written informed consent in accordance with the Declaration of Helsinki.
19-1	3063-3066	All	_
19-2	3067-3075	subjects	_
19-3	3076-3080	gave	_
19-4	3081-3088	written	_
19-5	3089-3097	informed	_
19-6	3098-3105	consent	_
19-7	3106-3108	in	_
19-8	3109-3119	accordance	_
19-9	3120-3124	with	_
19-10	3125-3128	the	_
19-11	3129-3140	Declaration	_
19-12	3141-3143	of	_
19-13	3144-3152	Helsinki	_
19-14	3153-3154	.	_

Text=Assessment of psychopathology Trained clinicians rated the severity of symptoms with the Scale for Assessment of Negative Symptoms (SANS) and the Scale for Assessment of Positive Symptoms (SAPS).
20-1	3155-3165	Assessment	_
20-2	3166-3168	of	_
20-3	3169-3184	psychopathology	_
20-4	3185-3192	Trained	_
20-5	3193-3203	clinicians	_
20-6	3204-3209	rated	_
20-7	3210-3213	the	_
20-8	3214-3222	severity	_
20-9	3223-3225	of	_
20-10	3226-3234	symptoms	_
20-11	3235-3239	with	_
20-12	3240-3243	the	_
20-13	3244-3249	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
20-14	3250-3253	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
20-15	3254-3264	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
20-16	3265-3267	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
20-17	3268-3276	Negative	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
20-18	3277-3285	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
20-19	3286-3287	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
20-20	3288-3292	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
20-21	3293-3294	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
20-22	3295-3298	and	_
20-23	3299-3302	the	_
20-24	3303-3308	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
20-25	3309-3312	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
20-26	3313-3323	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
20-27	3324-3326	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
20-28	3327-3335	Positive	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
20-29	3336-3344	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
20-30	3345-3346	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
20-31	3347-3351	SAPS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
20-32	3352-3353	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
20-33	3354-3355	.	_

Text=Table 1 includes details of patients ’ psychopathology.
21-1	3356-3361	Table	_
21-2	3362-3363	1	_
21-3	3364-3372	includes	_
21-4	3373-3380	details	_
21-5	3381-3383	of	_
21-6	3384-3392	patients	_
21-7	3393-3394	’	_
21-8	3395-3410	psychopathology	_
21-9	3411-3412	.	_

Text=The SANS assesses negative symptoms within the domains of affective blunting, alogia, avolition-apathy, anhedonia-asociality, attentional impairment and the SAPS assesses positive symptoms in the domains of hallucinations, delusions, bizarre behavior, and positive formal thought disorder.
22-1	3413-3416	The	_
22-2	3417-3421	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
22-3	3422-3430	assesses	_
22-4	3431-3439	negative	_
22-5	3440-3448	symptoms	_
22-6	3449-3455	within	_
22-7	3456-3459	the	_
22-8	3460-3467	domains	_
22-9	3468-3470	of	_
22-10	3471-3480	affective	_
22-11	3481-3489	blunting	_
22-12	3490-3491	,	_
22-13	3492-3498	alogia	_
22-14	3499-3500	,	_
22-15	3501-3517	avolition-apathy	_
22-16	3518-3519	,	_
22-17	3520-3540	anhedonia-asociality	_
22-18	3541-3542	,	_
22-19	3543-3554	attentional	_
22-20	3555-3565	impairment	_
22-21	3566-3569	and	_
22-22	3570-3573	the	_
22-23	3574-3578	SAPS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
22-24	3579-3587	assesses	_
22-25	3588-3596	positive	_
22-26	3597-3605	symptoms	_
22-27	3606-3608	in	_
22-28	3609-3612	the	_
22-29	3613-3620	domains	_
22-30	3621-3623	of	_
22-31	3624-3638	hallucinations	_
22-32	3639-3640	,	_
22-33	3641-3650	delusions	_
22-34	3651-3652	,	_
22-35	3653-3660	bizarre	_
22-36	3661-3669	behavior	_
22-37	3670-3671	,	_
22-38	3672-3675	and	_
22-39	3676-3684	positive	_
22-40	3685-3691	formal	_
22-41	3692-3699	thought	_
22-42	3700-3708	disorder	_
22-43	3709-3710	.	_

Text=Both scales rate severity of symptoms on a scale from 0 (absent) to 5 (severe).
23-1	3711-3715	Both	_
23-2	3716-3722	scales	_
23-3	3723-3727	rate	_
23-4	3728-3736	severity	_
23-5	3737-3739	of	_
23-6	3740-3748	symptoms	_
23-7	3749-3751	on	_
23-8	3752-3753	a	_
23-9	3754-3759	scale	_
23-10	3760-3764	from	_
23-11	3765-3766	0	_
23-12	3767-3768	(	_
23-13	3769-3775	absent	_
23-14	3776-3777	)	_
23-15	3778-3780	to	_
23-16	3781-3782	5	_
23-17	3783-3784	(	_
23-18	3785-3791	severe	_
23-19	3792-3793	)	_
23-20	3794-3795	.	_

Text=For both scales a composite score of all items was computed.
24-1	3796-3799	For	_
24-2	3800-3804	both	_
24-3	3805-3811	scales	_
24-4	3812-3813	a	_
24-5	3814-3823	composite	_
24-6	3824-3829	score	_
24-7	3830-3832	of	_
24-8	3833-3836	all	_
24-9	3837-3842	items	_
24-10	3843-3846	was	_
24-11	3847-3855	computed	_
24-12	3856-3857	.	_

Text=Additionally, both scales contain a global assessment item of each subdomain.
25-1	3858-3870	Additionally	_
25-2	3871-3872	,	_
25-3	3873-3877	both	_
25-4	3878-3884	scales	_
25-5	3885-3892	contain	_
25-6	3893-3894	a	_
25-7	3895-3901	global	_
25-8	3902-3912	assessment	_
25-9	3913-3917	item	_
25-10	3918-3920	of	_
25-11	3921-3925	each	_
25-12	3926-3935	subdomain	_
25-13	3936-3937	.	_

Text=MRI data acquisition Images were collected on a Siemens Tim Trio 3 T scanner (Erlangen, Germany) using a 12-channel head coil.
26-1	3938-3941	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
26-2	3942-3946	data	_
26-3	3947-3958	acquisition	_
26-4	3959-3965	Images	_
26-5	3966-3970	were	_
26-6	3971-3980	collected	_
26-7	3981-3983	on	_
26-8	3984-3985	a	_
26-9	3986-3993	Siemens	_
26-10	3994-3997	Tim	_
26-11	3998-4002	Trio	_
26-12	4003-4004	3	http://maven.renci.org/NeuroBridge/neurobridge#2Level
26-13	4005-4006	T	http://maven.renci.org/NeuroBridge/neurobridge#2Level
26-14	4007-4014	scanner	http://maven.renci.org/NeuroBridge/neurobridge#2Level
26-15	4015-4016	(	_
26-16	4017-4025	Erlangen	_
26-17	4026-4027	,	_
26-18	4028-4035	Germany	_
26-19	4036-4037	)	_
26-20	4038-4043	using	_
26-21	4044-4045	a	_
26-22	4046-4056	12-channel	_
26-23	4057-4061	head	_
26-24	4062-4066	coil	_
26-25	4067-4068	.	_

Text=Structural images were obtained using a T1-weighted magnetization prepared gradient-echo sequence (MPRAGE) based on the ADNI protocol (TR = 2500 ms; TE = 4.77 ms; TI = 1100 ms, acquisition matrix = 256 × 256 × 176; flip angle = 7°; 1 × 1 × 1 mm3 voxel size).
27-1	4069-4079	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
27-2	4080-4086	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
27-3	4087-4091	were	_
27-4	4092-4100	obtained	_
27-5	4101-4106	using	_
27-6	4107-4108	a	_
27-7	4109-4120	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
27-8	4121-4134	magnetization	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
27-9	4135-4143	prepared	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
27-10	4144-4157	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
27-11	4158-4166	sequence	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
27-12	4167-4168	(	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
27-13	4169-4175	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
27-14	4176-4177	)	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
27-15	4178-4183	based	_
27-16	4184-4186	on	_
27-17	4187-4190	the	_
27-18	4191-4195	ADNI	_
27-19	4196-4204	protocol	_
27-20	4205-4206	(	_
27-21	4207-4209	TR	_
27-22	4210-4211	=	_
27-23	4212-4216	2500	_
27-24	4217-4219	ms	_
27-25	4220-4221	;	_
27-26	4222-4224	TE	_
27-27	4225-4226	=	_
27-28	4227-4231	4.77	_
27-29	4232-4234	ms	_
27-30	4235-4236	;	_
27-31	4237-4239	TI	_
27-32	4240-4241	=	_
27-33	4242-4246	1100	_
27-34	4247-4249	ms	_
27-35	4250-4251	,	_
27-36	4252-4263	acquisition	_
27-37	4264-4270	matrix	_
27-38	4271-4272	=	_
27-39	4273-4276	256	_
27-40	4277-4278	×	_
27-41	4279-4282	256	_
27-42	4283-4284	×	_
27-43	4285-4288	176	_
27-44	4289-4290	;	_
27-45	4291-4295	flip	_
27-46	4296-4301	angle	_
27-47	4302-4303	=	_
27-48	4304-4306	7°	_
27-49	4307-4308	;	_
27-50	4309-4310	1	_
27-51	4311-4312	×	_
27-52	4313-4314	1	_
27-53	4315-4316	×	_
27-54	4317-4318	1	_
27-55	4319-4322	mm3	_
27-56	4323-4328	voxel	_
27-57	4329-4333	size	_
27-58	4334-4335	)	_
27-59	4336-4337	.	_

Text=Whole brain functional resting state images during 5 minutes were collected using a T2 * -weighted EPI sequence sensitive to BOLD contrast (TR = 2000 ms, TE = 30 ms, image matrix = 64 × 64, FOV = 216 mm, flip angle = 80°, slice thickness = 3.0 mm, distance factor = 20%, voxel size 3 × 3 × 3 mm3, 36 axial slices).
28-1	4338-4343	Whole	_
28-2	4344-4349	brain	_
28-3	4350-4360	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
28-4	4361-4368	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
28-5	4369-4374	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
28-6	4375-4381	images	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
28-7	4382-4388	during	_
28-8	4389-4390	5	_
28-9	4391-4398	minutes	_
28-10	4399-4403	were	_
28-11	4404-4413	collected	_
28-12	4414-4419	using	_
28-13	4420-4421	a	_
28-14	4422-4424	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
28-15	4425-4426	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
28-16	4427-4436	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
28-17	4437-4440	EPI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
28-18	4441-4449	sequence	_
28-19	4450-4459	sensitive	_
28-20	4460-4462	to	_
28-21	4463-4467	BOLD	_
28-22	4468-4476	contrast	_
28-23	4477-4478	(	_
28-24	4479-4481	TR	_
28-25	4482-4483	=	_
28-26	4484-4488	2000	_
28-27	4489-4491	ms	_
28-28	4492-4493	,	_
28-29	4494-4496	TE	_
28-30	4497-4498	=	_
28-31	4499-4501	30	_
28-32	4502-4504	ms	_
28-33	4505-4506	,	_
28-34	4507-4512	image	_
28-35	4513-4519	matrix	_
28-36	4520-4521	=	_
28-37	4522-4524	64	_
28-38	4525-4526	×	_
28-39	4527-4529	64	_
28-40	4530-4531	,	_
28-41	4532-4535	FOV	_
28-42	4536-4537	=	_
28-43	4538-4541	216	_
28-44	4542-4544	mm	_
28-45	4545-4546	,	_
28-46	4547-4551	flip	_
28-47	4552-4557	angle	_
28-48	4558-4559	=	_
28-49	4560-4563	80°	_
28-50	4564-4565	,	_
28-51	4566-4571	slice	_
28-52	4572-4581	thickness	_
28-53	4582-4583	=	_
28-54	4584-4587	3.0	_
28-55	4588-4590	mm	_
28-56	4591-4592	,	_
28-57	4593-4601	distance	_
28-58	4602-4608	factor	_
28-59	4609-4610	=	_
28-60	4611-4613	20	_
28-61	4614-4615	%	_
28-62	4616-4617	,	_
28-63	4618-4623	voxel	_
28-64	4624-4628	size	_
28-65	4629-4630	3	_
28-66	4631-4632	×	_
28-67	4633-4634	3	_
28-68	4635-4636	×	_
28-69	4637-4638	3	_
28-70	4639-4642	mm3	_
28-71	4643-4644	,	_
28-72	4645-4647	36	_
28-73	4648-4653	axial	_
28-74	4654-4660	slices	_
28-75	4661-4662	)	_
28-76	4663-4664	.	_

Text=Before resting state data acquisition was started, participants were in the scanner for about 10 minutes, during which a localizer and anatomical images were acquired so that subjects could get used to the scanner noise.
29-1	4665-4671	Before	_
29-2	4672-4679	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
29-3	4680-4685	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
29-4	4686-4690	data	_
29-5	4691-4702	acquisition	_
29-6	4703-4706	was	_
29-7	4707-4714	started	_
29-8	4715-4716	,	_
29-9	4717-4729	participants	_
29-10	4730-4734	were	_
29-11	4735-4737	in	_
29-12	4738-4741	the	_
29-13	4742-4749	scanner	_
29-14	4750-4753	for	_
29-15	4754-4759	about	_
29-16	4760-4762	10	_
29-17	4763-4770	minutes	_
29-18	4771-4772	,	_
29-19	4773-4779	during	_
29-20	4780-4785	which	_
29-21	4786-4787	a	_
29-22	4788-4797	localizer	_
29-23	4798-4801	and	_
29-24	4802-4812	anatomical	_
29-25	4813-4819	images	_
29-26	4820-4824	were	_
29-27	4825-4833	acquired	_
29-28	4834-4836	so	_
29-29	4837-4841	that	_
29-30	4842-4850	subjects	_
29-31	4851-4856	could	_
29-32	4857-4860	get	_
29-33	4861-4865	used	_
29-34	4866-4868	to	_
29-35	4869-4872	the	_
29-36	4873-4880	scanner	_
29-37	4881-4886	noise	_
29-38	4887-4888	.	_

Text=During resting state data acquisition, participants were asked to close their eyes and relax.
30-1	4889-4895	During	_
30-2	4896-4903	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-3	4904-4909	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-4	4910-4914	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-5	4915-4926	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-6	4927-4928	,	_
30-7	4929-4941	participants	_
30-8	4942-4946	were	_
30-9	4947-4952	asked	_
30-10	4953-4955	to	_
30-11	4956-4961	close	_
30-12	4962-4967	their	_
30-13	4968-4972	eyes	_
30-14	4973-4976	and	_
30-15	4977-4982	relax	_
30-16	4983-4984	.	_

Text=Preprocessing of resting state data To ensure for steady-state longitudinal magnetization, the first 5 images were discarded.
31-1	4985-4998	Preprocessing	_
31-2	4999-5001	of	_
31-3	5002-5009	resting	_
31-4	5010-5015	state	_
31-5	5016-5020	data	_
31-6	5021-5023	To	_
31-7	5024-5030	ensure	_
31-8	5031-5034	for	_
31-9	5035-5047	steady-state	_
31-10	5048-5060	longitudinal	_
31-11	5061-5074	magnetization	_
31-12	5075-5076	,	_
31-13	5077-5080	the	_
31-14	5081-5086	first	_
31-15	5087-5088	5	_
31-16	5089-5095	images	_
31-17	5096-5100	were	_
31-18	5101-5110	discarded	_
31-19	5111-5112	.	_

Text=The acquired data was corrected for slice timing and realigned.
32-1	5113-5116	The	_
32-2	5117-5125	acquired	_
32-3	5126-5130	data	_
32-4	5131-5134	was	_
32-5	5135-5144	corrected	_
32-6	5145-5148	for	_
32-7	5149-5154	slice	_
32-8	5155-5161	timing	_
32-9	5162-5165	and	_
32-10	5166-5175	realigned	_
32-11	5176-5177	.	_

Text=Structural individual T1 images were coregistered to functional images and segmented into gray matter, white matter, and cerebrospinal fluid.
33-1	5178-5188	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
33-2	5189-5199	individual	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
33-3	5200-5202	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-4	5203-5209	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-5	5210-5214	were	_
33-6	5215-5227	coregistered	_
33-7	5228-5230	to	_
33-8	5231-5241	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-9	5242-5248	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-10	5249-5252	and	_
33-11	5253-5262	segmented	_
33-12	5263-5267	into	_
33-13	5268-5272	gray	_
33-14	5273-5279	matter	_
33-15	5280-5281	,	_
33-16	5282-5287	white	_
33-17	5288-5294	matter	_
33-18	5295-5296	,	_
33-19	5297-5300	and	_
33-20	5301-5314	cerebrospinal	_
33-21	5315-5320	fluid	_
33-22	5321-5322	.	_

Text=Data was then spatially normalized to the MNI template and spatially smoothed with a 6-mm FWHM to improve signal-to-noise ratio.
34-1	5323-5327	Data	_
34-2	5328-5331	was	_
34-3	5332-5336	then	_
34-4	5337-5346	spatially	_
34-5	5347-5357	normalized	_
34-6	5358-5360	to	_
34-7	5361-5364	the	_
34-8	5365-5368	MNI	_
34-9	5369-5377	template	_
34-10	5378-5381	and	_
34-11	5382-5391	spatially	_
34-12	5392-5400	smoothed	_
34-13	5401-5405	with	_
34-14	5406-5407	a	_
34-15	5408-5412	6-mm	_
34-16	5413-5417	FWHM	_
34-17	5418-5420	to	_
34-18	5421-5428	improve	_
34-19	5429-5444	signal-to-noise	_
34-20	5445-5450	ratio	_
34-21	5451-5452	.	_

Text=All steps of data preprocessing were performed using SPM12.
35-1	5453-5456	All	_
35-2	5457-5462	steps	_
35-3	5463-5465	of	_
35-4	5466-5470	data	_
35-5	5471-5484	preprocessing	_
35-6	5485-5489	were	_
35-7	5490-5499	performed	_
35-8	5500-5505	using	_
35-9	5506-5511	SPM12	_
35-10	5512-5513	.	_

Text=In addition, to control for motion, we used the voxel-specific mean frame-wise displacement (FD).
36-1	5514-5516	In	_
36-2	5517-5525	addition	_
36-3	5526-5527	,	_
36-4	5528-5530	to	_
36-5	5531-5538	control	_
36-6	5539-5542	for	_
36-7	5543-5549	motion	_
36-8	5550-5551	,	_
36-9	5552-5554	we	_
36-10	5555-5559	used	_
36-11	5560-5563	the	_
36-12	5564-5578	voxel-specific	_
36-13	5579-5583	mean	_
36-14	5584-5594	frame-wise	_
36-15	5595-5607	displacement	_
36-16	5608-5609	(	_
36-17	5610-5612	FD	_
36-18	5613-5614	)	_
36-19	5615-5616	.	_

Text=FD values were below the default threshold of 0.5 for control and patient group (0.15 ± 0.02 and 0.17 ± 0.02, t-test p = 0.42).
37-1	5617-5619	FD	_
37-2	5620-5626	values	_
37-3	5627-5631	were	_
37-4	5632-5637	below	_
37-5	5638-5641	the	_
37-6	5642-5649	default	_
37-7	5650-5659	threshold	_
37-8	5660-5662	of	_
37-9	5663-5666	0.5	_
37-10	5667-5670	for	_
37-11	5671-5678	control	_
37-12	5679-5682	and	_
37-13	5683-5690	patient	_
37-14	5691-5696	group	_
37-15	5697-5698	(	_
37-16	5699-5703	0.15	_
37-17	5704-5705	±	_
37-18	5706-5710	0.02	_
37-19	5711-5714	and	_
37-20	5715-5719	0.17	_
37-21	5720-5721	±	_
37-22	5722-5726	0.02	_
37-23	5727-5728	,	_
37-24	5729-5735	t-test	_
37-25	5736-5737	p	_
37-26	5738-5739	=	_
37-27	5740-5744	0.42	_
37-28	5745-5746	)	_
37-29	5747-5748	.	_

Text=Independent component analysis (ICA) ICA is a data-driven analysis tool in which source signals are blindly recovered from mixtures of sources.
38-1	5749-5760	Independent	_
38-2	5761-5770	component	_
38-3	5771-5779	analysis	_
38-4	5780-5781	(	_
38-5	5782-5785	ICA	_
38-6	5786-5787	)	_
38-7	5788-5791	ICA	_
38-8	5792-5794	is	_
38-9	5795-5796	a	_
38-10	5797-5808	data-driven	_
38-11	5809-5817	analysis	_
38-12	5818-5822	tool	_
38-13	5823-5825	in	_
38-14	5826-5831	which	_
38-15	5832-5838	source	_
38-16	5839-5846	signals	_
38-17	5847-5850	are	_
38-18	5851-5858	blindly	_
38-19	5859-5868	recovered	_
38-20	5869-5873	from	_
38-21	5874-5882	mixtures	_
38-22	5883-5885	of	_
38-23	5886-5893	sources	_
38-24	5894-5895	.	_

Text=ICA was calculated using GIFT software (http: //icatb.sourceforge.net/) in Matlab 2012b using Infomax algorithm to estimate independent sources.
39-1	5896-5899	ICA	_
39-2	5900-5903	was	_
39-3	5904-5914	calculated	_
39-4	5915-5920	using	_
39-5	5921-5925	GIFT	_
39-6	5926-5934	software	_
39-7	5935-5936	(	_
39-8	5937-5941	http	_
39-9	5942-5943	:	_
39-10	5944-5968	//icatb.sourceforge.net/	_
39-11	5969-5970	)	_
39-12	5971-5973	in	_
39-13	5974-5980	Matlab	_
39-14	5981-5986	2012b	_
39-15	5987-5992	using	_
39-16	5993-6000	Infomax	_
39-17	6001-6010	algorithm	_
39-18	6011-6013	to	_
39-19	6014-6022	estimate	_
39-20	6023-6034	independent	_
39-21	6035-6042	sources	_
39-22	6043-6044	.	_

Text=ICA was run 20 times and the results were clustered by GIFT toolbox ICASSO min cluster size of 16 and max of 20 (number of runs) and RandInit and Bootstrap were selected.
40-1	6045-6048	ICA	_
40-2	6049-6052	was	_
40-3	6053-6056	run	_
40-4	6057-6059	20	_
40-5	6060-6065	times	_
40-6	6066-6069	and	_
40-7	6070-6073	the	_
40-8	6074-6081	results	_
40-9	6082-6086	were	_
40-10	6087-6096	clustered	_
40-11	6097-6099	by	_
40-12	6100-6104	GIFT	_
40-13	6105-6112	toolbox	_
40-14	6113-6119	ICASSO	_
40-15	6120-6123	min	_
40-16	6124-6131	cluster	_
40-17	6132-6136	size	_
40-18	6137-6139	of	_
40-19	6140-6142	16	_
40-20	6143-6146	and	_
40-21	6147-6150	max	_
40-22	6151-6153	of	_
40-23	6154-6156	20	_
40-24	6157-6158	(	_
40-25	6159-6165	number	_
40-26	6166-6168	of	_
40-27	6169-6173	runs	_
40-28	6174-6175	)	_
40-29	6176-6179	and	_
40-30	6180-6188	RandInit	_
40-31	6189-6192	and	_
40-32	6193-6202	Bootstrap	_
40-33	6203-6207	were	_
40-34	6208-6216	selected	_
40-35	6217-6218	.	_

Text=Preprocessed data from all subjects in both groups were used.
41-1	6219-6231	Preprocessed	_
41-2	6232-6236	data	_
41-3	6237-6241	from	_
41-4	6242-6245	all	_
41-5	6246-6254	subjects	_
41-6	6255-6257	in	_
41-7	6258-6262	both	_
41-8	6263-6269	groups	_
41-9	6270-6274	were	_
41-10	6275-6279	used	_
41-11	6280-6281	.	_

Text=The optimal number of spatially independent resting-state networks (N) to be extracted was estimated by the software (N = 21; see Supplemental Material Fig.
42-1	6282-6285	The	_
42-2	6286-6293	optimal	_
42-3	6294-6300	number	_
42-4	6301-6303	of	_
42-5	6304-6313	spatially	_
42-6	6314-6325	independent	_
42-7	6326-6339	resting-state	_
42-8	6340-6348	networks	_
42-9	6349-6350	(	_
42-10	6351-6352	N	_
42-11	6353-6354	)	_
42-12	6355-6357	to	_
42-13	6358-6360	be	_
42-14	6361-6370	extracted	_
42-15	6371-6374	was	_
42-16	6375-6384	estimated	_
42-17	6385-6387	by	_
42-18	6388-6391	the	_
42-19	6392-6400	software	_
42-20	6401-6402	(	_
42-21	6403-6404	N	_
42-22	6405-6406	=	_
42-23	6407-6409	21	_
42-24	6410-6411	;	_
42-25	6412-6415	see	_
42-26	6416-6428	Supplemental	_
42-27	6429-6437	Material	_
42-28	6438-6441	Fig	_
42-29	6442-6443	.	_

Text=S1).
43-1	6444-6446	S1	_
43-2	6447-6448	)	_
43-3	6449-6450	.	_

Text=Only components with ICASO stability index Iq of> 0.9 were considered and the related spatial maps.
44-1	6451-6455	Only	_
44-2	6456-6466	components	_
44-3	6467-6471	with	_
44-4	6472-6477	ICASO	_
44-5	6478-6487	stability	_
44-6	6488-6493	index	_
44-7	6494-6496	Iq	_
44-8	6497-6499	of	_
44-9	6500-6501	>	_
44-10	6502-6505	0.9	_
44-11	6506-6510	were	_
44-12	6511-6521	considered	_
44-13	6522-6525	and	_
44-14	6526-6529	the	_
44-15	6530-6537	related	_
44-16	6538-6545	spatial	_
44-17	6546-6550	maps	_
44-18	6551-6552	.	_

Text=The networks were identified using predefined templates in GIFT and a-posteriori by experts C.G.F and S.K.
45-1	6553-6556	The	_
45-2	6557-6565	networks	_
45-3	6566-6570	were	_
45-4	6571-6581	identified	_
45-5	6582-6587	using	_
45-6	6588-6598	predefined	_
45-7	6599-6608	templates	_
45-8	6609-6611	in	_
45-9	6612-6616	GIFT	_
45-10	6617-6620	and	_
45-11	6621-6633	a-posteriori	_
45-12	6634-6636	by	_
45-13	6637-6644	experts	_
45-14	6645-6650	C.G.F	_
45-15	6651-6654	and	_
45-16	6655-6658	S.K	_
45-17	6659-6660	.	_

Text=Among the ICA components, the default mode network was identified and taken to the second level analysis in SPM12 using a mask for individual networks provided by http: //findlab.stanford.edu/functional_ROIs.html.
46-1	6661-6666	Among	_
46-2	6667-6670	the	_
46-3	6671-6674	ICA	_
46-4	6675-6685	components	_
46-5	6686-6687	,	_
46-6	6688-6691	the	_
46-7	6692-6699	default	_
46-8	6700-6704	mode	_
46-9	6705-6712	network	_
46-10	6713-6716	was	_
46-11	6717-6727	identified	_
46-12	6728-6731	and	_
46-13	6732-6737	taken	_
46-14	6738-6740	to	_
46-15	6741-6744	the	_
46-16	6745-6751	second	_
46-17	6752-6757	level	_
46-18	6758-6766	analysis	_
46-19	6767-6769	in	_
46-20	6770-6775	SPM12	_
46-21	6776-6781	using	_
46-22	6782-6783	a	_
46-23	6784-6788	mask	_
46-24	6789-6792	for	_
46-25	6793-6803	individual	_
46-26	6804-6812	networks	_
46-27	6813-6821	provided	_
46-28	6822-6824	by	_
46-29	6825-6829	http	_
46-30	6830-6831	:	_
46-31	6832-6875	//findlab.stanford.edu/functional_ROIs.html	_
46-32	6876-6877	.	_

Text=To make use of the full potentiality of the method, we conducted an exploratory analysis selecting the following networks that were concomitantly extracted by ICA (Fig.
47-1	6878-6880	To	_
47-2	6881-6885	make	_
47-3	6886-6889	use	_
47-4	6890-6892	of	_
47-5	6893-6896	the	_
47-6	6897-6901	full	_
47-7	6902-6914	potentiality	_
47-8	6915-6917	of	_
47-9	6918-6921	the	_
47-10	6922-6928	method	_
47-11	6929-6930	,	_
47-12	6931-6933	we	_
47-13	6934-6943	conducted	_
47-14	6944-6946	an	_
47-15	6947-6958	exploratory	_
47-16	6959-6967	analysis	_
47-17	6968-6977	selecting	_
47-18	6978-6981	the	_
47-19	6982-6991	following	_
47-20	6992-7000	networks	_
47-21	7001-7005	that	_
47-22	7006-7010	were	_
47-23	7011-7024	concomitantly	_
47-24	7025-7034	extracted	_
47-25	7035-7037	by	_
47-26	7038-7041	ICA	_
47-27	7042-7043	(	_
47-28	7044-7047	Fig	_
47-29	7048-7049	.	_

Text=S1 in Supplemental Material): basal ganglia, visual, salience, auditory, executive control, and visuospatial.
48-1	7050-7052	S1	_
48-2	7053-7055	in	_
48-3	7056-7068	Supplemental	_
48-4	7069-7077	Material	_
48-5	7078-7079	)	_
48-6	7080-7081	:	_
48-7	7082-7087	basal	_
48-8	7088-7095	ganglia	_
48-9	7096-7097	,	_
48-10	7098-7104	visual	_
48-11	7105-7106	,	_
48-12	7107-7115	salience	_
48-13	7116-7117	,	_
48-14	7118-7126	auditory	_
48-15	7127-7128	,	_
48-16	7129-7138	executive	_
48-17	7139-7146	control	_
48-18	7147-7148	,	_
48-19	7149-7152	and	_
48-20	7153-7165	visuospatial	_
48-21	7166-7167	.	_

Text=Differences between groups were calculated using a two-sample t-test (p = 0.001 uncorrected), significant threshold was set to p <0.05 corrected for multiple comparison using family wise error (FWE) at cluster-level.
49-1	7168-7179	Differences	_
49-2	7180-7187	between	_
49-3	7188-7194	groups	_
49-4	7195-7199	were	_
49-5	7200-7210	calculated	_
49-6	7211-7216	using	_
49-7	7217-7218	a	_
49-8	7219-7229	two-sample	_
49-9	7230-7236	t-test	_
49-10	7237-7238	(	_
49-11	7239-7240	p	_
49-12	7241-7242	=	_
49-13	7243-7248	0.001	_
49-14	7249-7260	uncorrected	_
49-15	7261-7262	)	_
49-16	7263-7264	,	_
49-17	7265-7276	significant	_
49-18	7277-7286	threshold	_
49-19	7287-7290	was	_
49-20	7291-7294	set	_
49-21	7295-7297	to	_
49-22	7298-7299	p	_
49-23	7300-7301	<	_
49-24	7302-7306	0.05	_
49-25	7307-7316	corrected	_
49-26	7317-7320	for	_
49-27	7321-7329	multiple	_
49-28	7330-7340	comparison	_
49-29	7341-7346	using	_
49-30	7347-7353	family	_
49-31	7354-7358	wise	_
49-32	7359-7364	error	_
49-33	7365-7366	(	_
49-34	7367-7370	FWE	_
49-35	7371-7372	)	_
49-36	7373-7375	at	_
49-37	7376-7389	cluster-level	_
49-38	7390-7391	.	_

Text=Mean FD, gender and age were used as covariates.
50-1	7392-7396	Mean	_
50-2	7397-7399	FD	_
50-3	7400-7401	,	_
50-4	7402-7408	gender	_
50-5	7409-7412	and	_
50-6	7413-7416	age	_
50-7	7417-7421	were	_
50-8	7422-7426	used	_
50-9	7427-7429	as	_
50-10	7430-7440	covariates	_
50-11	7441-7442	.	_

Text=In those clusters where we found significant group differences, we extracted the mean absolute ICA values (spatial maps) for each subject for a posteriori correlation analysis of functional connectivity with psychopathology.
51-1	7443-7445	In	_
51-2	7446-7451	those	_
51-3	7452-7460	clusters	_
51-4	7461-7466	where	_
51-5	7467-7469	we	_
51-6	7470-7475	found	_
51-7	7476-7487	significant	_
51-8	7488-7493	group	_
51-9	7494-7505	differences	_
51-10	7506-7507	,	_
51-11	7508-7510	we	_
51-12	7511-7520	extracted	_
51-13	7521-7524	the	_
51-14	7525-7529	mean	_
51-15	7530-7538	absolute	_
51-16	7539-7542	ICA	_
51-17	7543-7549	values	_
51-18	7550-7551	(	_
51-19	7552-7559	spatial	_
51-20	7560-7564	maps	_
51-21	7565-7566	)	_
51-22	7567-7570	for	_
51-23	7571-7575	each	_
51-24	7576-7583	subject	_
51-25	7584-7587	for	_
51-26	7588-7589	a	_
51-27	7590-7600	posteriori	_
51-28	7601-7612	correlation	_
51-29	7613-7621	analysis	_
51-30	7622-7624	of	_
51-31	7625-7635	functional	_
51-32	7636-7648	connectivity	_
51-33	7649-7653	with	_
51-34	7654-7669	psychopathology	_
51-35	7670-7671	.	_

Text=Correlation with psychopathology To investigate whether these differences in resting state networks between healthy individuals and patients with schizophrenia were related to the psychopathology of patients, Spearman ’ s correlation coefficients between resting state network connectivity and severity of symptoms were calculated.
52-1	7672-7683	Correlation	_
52-2	7684-7688	with	_
52-3	7689-7704	psychopathology	_
52-4	7705-7707	To	_
52-5	7708-7719	investigate	_
52-6	7720-7727	whether	_
52-7	7728-7733	these	_
52-8	7734-7745	differences	_
52-9	7746-7748	in	_
52-10	7749-7756	resting	_
52-11	7757-7762	state	_
52-12	7763-7771	networks	_
52-13	7772-7779	between	_
52-14	7780-7787	healthy	_
52-15	7788-7799	individuals	_
52-16	7800-7803	and	_
52-17	7804-7812	patients	_
52-18	7813-7817	with	_
52-19	7818-7831	schizophrenia	_
52-20	7832-7836	were	_
52-21	7837-7844	related	_
52-22	7845-7847	to	_
52-23	7848-7851	the	_
52-24	7852-7867	psychopathology	_
52-25	7868-7870	of	_
52-26	7871-7879	patients	_
52-27	7880-7881	,	_
52-28	7882-7890	Spearman	_
52-29	7891-7892	’	_
52-30	7893-7894	s	_
52-31	7895-7906	correlation	_
52-32	7907-7919	coefficients	_
52-33	7920-7927	between	_
52-34	7928-7935	resting	_
52-35	7936-7941	state	_
52-36	7942-7949	network	_
52-37	7950-7962	connectivity	_
52-38	7963-7966	and	_
52-39	7967-7975	severity	_
52-40	7976-7978	of	_
52-41	7979-7987	symptoms	_
52-42	7988-7992	were	_
52-43	7993-8003	calculated	_
52-44	8004-8005	.	_

Text=The resting state functional connectivity was extracted from the cluster in the DMN in which we found group differences: for each subject we extracted the mean absolute ICA value (spatial maps).
53-1	8006-8009	The	_
53-2	8010-8017	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
53-3	8018-8023	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
53-4	8024-8034	functional	_
53-5	8035-8047	connectivity	_
53-6	8048-8051	was	_
53-7	8052-8061	extracted	_
53-8	8062-8066	from	_
53-9	8067-8070	the	_
53-10	8071-8078	cluster	_
53-11	8079-8081	in	_
53-12	8082-8085	the	_
53-13	8086-8089	DMN	_
53-14	8090-8092	in	_
53-15	8093-8098	which	_
53-16	8099-8101	we	_
53-17	8102-8107	found	_
53-18	8108-8113	group	_
53-19	8114-8125	differences	_
53-20	8126-8127	:	_
53-21	8128-8131	for	_
53-22	8132-8136	each	_
53-23	8137-8144	subject	_
53-24	8145-8147	we	_
53-25	8148-8157	extracted	_
53-26	8158-8161	the	_
53-27	8162-8166	mean	_
53-28	8167-8175	absolute	_
53-29	8176-8179	ICA	_
53-30	8180-8185	value	_
53-31	8186-8187	(	_
53-32	8188-8195	spatial	_
53-33	8196-8200	maps	_
53-34	8201-8202	)	_
53-35	8203-8204	.	_

Text=In a first step, we correlated the functional connectivity in the DMN cluster with the composite scores of the SANS and SAPS.
54-1	8205-8207	In	_
54-2	8208-8209	a	_
54-3	8210-8215	first	_
54-4	8216-8220	step	_
54-5	8221-8222	,	_
54-6	8223-8225	we	_
54-7	8226-8236	correlated	_
54-8	8237-8240	the	_
54-9	8241-8251	functional	_
54-10	8252-8264	connectivity	_
54-11	8265-8267	in	_
54-12	8268-8271	the	_
54-13	8272-8275	DMN	_
54-14	8276-8283	cluster	_
54-15	8284-8288	with	_
54-16	8289-8292	the	_
54-17	8293-8302	composite	_
54-18	8303-8309	scores	_
54-19	8310-8312	of	_
54-20	8313-8316	the	_
54-21	8317-8321	SANS	_
54-22	8322-8325	and	_
54-23	8326-8330	SAPS	_
54-24	8331-8332	.	_

Text=In case of a significant correlation, we conducted further exploratory correlations with the global ratings of the associated symptom domains.
55-1	8333-8335	In	_
55-2	8336-8340	case	_
55-3	8341-8343	of	_
55-4	8344-8345	a	_
55-5	8346-8357	significant	_
55-6	8358-8369	correlation	_
55-7	8370-8371	,	_
55-8	8372-8374	we	_
55-9	8375-8384	conducted	_
55-10	8385-8392	further	_
55-11	8393-8404	exploratory	_
55-12	8405-8417	correlations	_
55-13	8418-8422	with	_
55-14	8423-8426	the	_
55-15	8427-8433	global	_
55-16	8434-8441	ratings	_
55-17	8442-8444	of	_
55-18	8445-8448	the	_
55-19	8449-8459	associated	_
55-20	8460-8467	symptom	_
55-21	8468-8475	domains	_
55-22	8476-8477	.	_

Text=Statistical analysis was performed using SPSS 22.
56-1	8478-8489	Statistical	_
56-2	8490-8498	analysis	_
56-3	8499-8502	was	_
56-4	8503-8512	performed	_
56-5	8513-8518	using	_
56-6	8519-8523	SPSS	_
56-7	8524-8526	22	_
56-8	8527-8528	.	_

Text=For the correlation with the SAPS and SANS composite scores, a Bonferroni adjusted significance level of 0.025 (0.05/2) was applied.
57-1	8529-8532	For	_
57-2	8533-8536	the	_
57-3	8537-8548	correlation	_
57-4	8549-8553	with	_
57-5	8554-8557	the	_
57-6	8558-8562	SAPS	_
57-7	8563-8566	and	_
57-8	8567-8571	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
57-9	8572-8581	composite	_
57-10	8582-8588	scores	_
57-11	8589-8590	,	_
57-12	8591-8592	a	_
57-13	8593-8603	Bonferroni	_
57-14	8604-8612	adjusted	_
57-15	8613-8625	significance	_
57-16	8626-8631	level	_
57-17	8632-8634	of	_
57-18	8635-8640	0.025	_
57-19	8641-8642	(	_
57-20	8643-8649	0.05/2	_
57-21	8650-8651	)	_
57-22	8652-8655	was	_
57-23	8656-8663	applied	_
57-24	8664-8665	.	_

Text=For the correlations with subdomains we used a Bonferroni corrected alpha value of 0.0125 (0.05/4) for the SAPS and of 0.01 (0.05/5) for the SANS.
58-1	8666-8669	For	_
58-2	8670-8673	the	_
58-3	8674-8686	correlations	_
58-4	8687-8691	with	_
58-5	8692-8702	subdomains	_
58-6	8703-8705	we	_
58-7	8706-8710	used	_
58-8	8711-8712	a	_
58-9	8713-8723	Bonferroni	_
58-10	8724-8733	corrected	_
58-11	8734-8739	alpha	_
58-12	8740-8745	value	_
58-13	8746-8748	of	_
58-14	8749-8755	0.0125	_
58-15	8756-8757	(	_
58-16	8758-8764	0.05/4	_
58-17	8765-8766	)	_
58-18	8767-8770	for	_
58-19	8771-8774	the	_
58-20	8775-8779	SAPS	_
58-21	8780-8783	and	_
58-22	8784-8786	of	_
58-23	8787-8791	0.01	_
58-24	8792-8793	(	_
58-25	8794-8800	0.05/5	_
58-26	8801-8802	)	_
58-27	8803-8806	for	_
58-28	8807-8810	the	_
58-29	8811-8815	SANS	_
58-30	8816-8817	.	_

